• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

活化的人CD4⁺ T细胞上CD83的持续表达与其分化为诱导性调节性T细胞相关。

Continuous expression of CD83 on activated human CD4⁺ T cells is correlated with their differentiation into induced regulatory T cells.

作者信息

Chen Liwen, Guan Shihe, Zhou Qiang, Sheng Shouqin, Zhong Fei, Wang Qin

机构信息

Department of Laboratory Medicine, The Second Hospital of Anhui Medical University, Hefei, Anhui 230601, P.R. China.

Department of Medical Research Center, The Second Hospital of Anhui Medical University, Hefei, Anhui 230601, P.R. China.

出版信息

Mol Med Rep. 2015 Sep;12(3):3309-3314. doi: 10.3892/mmr.2015.3796. Epub 2015 May 18.

DOI:10.3892/mmr.2015.3796
PMID:25997495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4526085/
Abstract

CD83 is a widely recognized surface marker for mature dendritic cells, which are essential for priming naïve CD4+ T cells into effector cells. However, CD83 is also expressed on activated CD4+ T cells, which remains an enigma in T‑cell mediated immunity. Therefore, the identification of the biological features and regulation of the expression of CD83 on activated CD4+ T cells is important in understanding the function of CD83 in the adaptive immune response. The present study revealed a time‑dependent manner of the expression of CD83 on anti‑CD3/CD28‑stimulated human CD4+ T cells, which is characterized by the maximum expression at day 2 and a significant decrease at day 3. The reduced expression is not a result of a reduced rate of cell proliferation. The activation of interleukin‑2 and secretion of interferon‑γ accumulated progressively from day 1 to 3. Of note, sustained expression of CD83 was observed when CD4+ T cells were induced by transforming growth factor-β to differentiate into CD4+CD25+ forkhead box P3+ regulatory T (iTreg) cells. Confocal immunofluorescence microscopy analysis demonstrated that CD83 was highly co‑localized with CD25 on activated CD4+ T cells. In conclusion, the findings of the present study suggested that the continuous expression of CD83 on activated human CD4+ T cells is correlated with their differentiation into iTreg cells.

摘要

CD83是成熟树突状细胞广泛认可的表面标志物,而成熟树突状细胞对于将初始CD4+ T细胞启动分化为效应细胞至关重要。然而,CD83也在活化的CD4+ T细胞上表达,这在T细胞介导的免疫中仍是一个谜。因此,鉴定活化的CD4+ T细胞上CD83的生物学特性及其表达调控,对于理解CD83在适应性免疫应答中的功能很重要。本研究揭示了抗CD3/CD28刺激的人CD4+ T细胞上CD83表达的时间依赖性方式,其特征是在第2天表达最高,在第3天显著下降。表达降低并非细胞增殖速率降低的结果。从第1天到第3天,白细胞介素-2的激活和干扰素-γ的分泌逐渐积累。值得注意的是,当CD4+ T细胞被转化生长因子-β诱导分化为CD4+CD25+叉头框P3+调节性T(iTreg)细胞时,观察到CD83的持续表达。共聚焦免疫荧光显微镜分析表明,CD83在活化的CD4+ T细胞上与CD25高度共定位。总之,本研究结果表明,活化的人CD4+ T细胞上CD83的持续表达与其分化为iTreg细胞相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec9c/4526085/c49285228e36/MMR-12-03-3309-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec9c/4526085/b7c2748b6ed1/MMR-12-03-3309-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec9c/4526085/650b8b497de5/MMR-12-03-3309-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec9c/4526085/8c957480565b/MMR-12-03-3309-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec9c/4526085/c49285228e36/MMR-12-03-3309-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec9c/4526085/b7c2748b6ed1/MMR-12-03-3309-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec9c/4526085/650b8b497de5/MMR-12-03-3309-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec9c/4526085/8c957480565b/MMR-12-03-3309-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec9c/4526085/c49285228e36/MMR-12-03-3309-g03.jpg

相似文献

1
Continuous expression of CD83 on activated human CD4⁺ T cells is correlated with their differentiation into induced regulatory T cells.活化的人CD4⁺ T细胞上CD83的持续表达与其分化为诱导性调节性T细胞相关。
Mol Med Rep. 2015 Sep;12(3):3309-3314. doi: 10.3892/mmr.2015.3796. Epub 2015 May 18.
2
IL-10-Modulated Human Dendritic Cells for Clinical Use: Identification of a Stable and Migratory Subset with Improved Tolerogenic Activity.用于临床的白细胞介素-10调节的人树突状细胞:具有增强的致耐受性活性的稳定迁移亚群的鉴定
J Immunol. 2016 Nov 1;197(9):3607-3617. doi: 10.4049/jimmunol.1501769. Epub 2016 Sep 28.
3
CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo.CD83表达是体内B细胞和CD4+T细胞长寿所需激活的敏感标志物。
J Immunol. 2007 Oct 1;179(7):4550-62. doi: 10.4049/jimmunol.179.7.4550.
4
CD83 Antibody Inhibits Human B Cell Responses to Antigen as well as Dendritic Cell-Mediated CD4 T Cell Responses.CD83 抗体抑制人类 B 细胞对抗原的反应以及树突状细胞介导的 CD4 T 细胞反应。
J Immunol. 2018 May 15;200(10):3383-3396. doi: 10.4049/jimmunol.1700064. Epub 2018 Apr 11.
5
CD83 expression in CD4+ T cells modulates inflammation and autoimmunity.CD4+ T细胞中的CD83表达调节炎症和自身免疫。
J Immunol. 2008 May 1;180(9):5890-7. doi: 10.4049/jimmunol.180.9.5890.
6
Endogenous CD83 Expression in CD4 Conventional T Cells Controls Inflammatory Immune Responses.CD4 常规 T 细胞中的内源性 CD83 表达控制炎症免疫反应。
J Immunol. 2020 Jun 15;204(12):3217-3226. doi: 10.4049/jimmunol.2000042. Epub 2020 Apr 27.
7
Differentiation of naive CD4+ T cells into CD4+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation.通过持续抗原刺激将初始CD4+ T细胞分化为CD4+CD25+FOXP3+调节性T细胞。
J Leukoc Biol. 2008 May;83(5):1111-7. doi: 10.1189/jlb.0507329. Epub 2008 Feb 12.
8
CD83: a regulatory molecule of the immune system with great potential for therapeutic application.CD83:一种免疫系统的调节分子,具有巨大的治疗应用潜力。
J Med Dent Sci. 2006 Jun;53(2):85-91.
9
Endogenous Expression of the Human CD83 Attenuates EAE Symptoms in Humanized Transgenic Mice and Increases the Activity of Regulatory T Cells.内源性表达人 CD83 可减轻人源化转基因小鼠的 EAE 症状并增加调节性 T 细胞的活性。
Front Immunol. 2019 Jun 25;10:1442. doi: 10.3389/fimmu.2019.01442. eCollection 2019.
10
Role of CD83 in the immunomodulation of dendritic cells.CD83在树突状细胞免疫调节中的作用。
Int Arch Allergy Immunol. 2002 Oct;129(2):113-8. doi: 10.1159/000065883.

引用本文的文献

1
Selective expansion of TCF7-expressing tumor-reactive T cell subpopulations during ovarian tumor-infiltrating T cell production ex vivo.在体外产生卵巢肿瘤浸润性T细胞过程中,表达TCF7的肿瘤反应性T细胞亚群的选择性扩增。
Sci China Life Sci. 2025 Jul 8. doi: 10.1007/s11427-025-2958-3.
2
CD83 Regulates the Immune Responses in Inflammatory Disorders.CD83 调节炎症性疾病中的免疫反应。
Int J Mol Sci. 2023 Feb 1;24(3):2831. doi: 10.3390/ijms24032831.
3
Tilting the Balance: Therapeutic Prospects of CD83 as a Checkpoint Molecule Controlling Resolution of Inflammation.

本文引用的文献

1
The expression and characterization of functionally active soluble CD83 by Pichia pastoris using high-density fermentation.利用高密度发酵通过毕赤酵母表达和鉴定功能活性可溶性CD83
PLoS One. 2014 Feb 20;9(2):e89264. doi: 10.1371/journal.pone.0089264. eCollection 2014.
2
Dendritic cell membrane CD83 enhances immune responses by boosting intracellular calcium release in T lymphocytes.树突状细胞膜 CD83 通过增强 T 淋巴细胞内的钙释放来增强免疫反应。
J Leukoc Biol. 2014 May;95(5):755-762. doi: 10.1189/jlb.0413239. Epub 2014 Jan 16.
3
Soluble CD83 ameliorates experimental colitis in mice.
倾斜天平:CD83 作为控制炎症消退的检查点分子的治疗前景。
Int J Mol Sci. 2022 Jan 10;23(2):732. doi: 10.3390/ijms23020732.
4
The CD83 Molecule - An Important Immune Checkpoint.CD83 分子——一个重要的免疫检查点。
Front Immunol. 2020 Apr 17;11:721. doi: 10.3389/fimmu.2020.00721. eCollection 2020.
5
Endogenous Expression of the Human CD83 Attenuates EAE Symptoms in Humanized Transgenic Mice and Increases the Activity of Regulatory T Cells.内源性表达人 CD83 可减轻人源化转基因小鼠的 EAE 症状并增加调节性 T 细胞的活性。
Front Immunol. 2019 Jun 25;10:1442. doi: 10.3389/fimmu.2019.01442. eCollection 2019.
6
CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.CD83:抗原提呈细胞的激活标志物及其治疗潜力。
Front Immunol. 2019 Jun 7;10:1312. doi: 10.3389/fimmu.2019.01312. eCollection 2019.
7
The Nucleocapsid Protein and Nonstructural Protein 10 of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus Enhance CD83 Production via NF-κB and Sp1 Signaling Pathways.高致病性猪繁殖与呼吸综合征病毒的核衣壳蛋白和非结构蛋白10通过NF-κB和Sp1信号通路增强CD83的产生。
J Virol. 2017 Aug 24;91(18). doi: 10.1128/JVI.00986-17. Print 2017 Sep 15.
8
A Kinetic Study of CD83 Reveals an Upregulation and Higher Production of sCD83 in Lymphocytes from Pregnant Mice.CD83的动力学研究揭示了妊娠小鼠淋巴细胞中可溶性CD83的上调和更高产量。
Front Immunol. 2017 Apr 26;8:486. doi: 10.3389/fimmu.2017.00486. eCollection 2017.
可溶性 CD83 可改善小鼠实验性结肠炎。
Mucosal Immunol. 2014 Jul;7(4):1006-18. doi: 10.1038/mi.2013.119. Epub 2014 Jan 15.
4
CD4+CD25+ T regs with acetylated FoxP3 are associated with immune suppression in human leprosy.CD4+CD25+ T 调节细胞中乙酰化 FoxP3 与人类麻风病的免疫抑制有关。
Mol Immunol. 2013 Dec;56(4):513-20. doi: 10.1016/j.molimm.2013.04.015. Epub 2013 Aug 1.
5
Soluble human CD83 ameliorates lupus in NZB/W F1 mice.可溶性人 CD83 可改善 NZB/W F1 小鼠的狼疮。
Immunobiology. 2013 Nov;218(11):1411-5. doi: 10.1016/j.imbio.2013.06.002. Epub 2013 Jun 17.
6
Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival.局部应用可溶性 CD83 诱导 IDO 介导的免疫调节,增加 Foxp3+ T 细胞,并延长同种异体角膜移植物的存活。
J Immunol. 2013 Aug 15;191(4):1965-75. doi: 10.4049/jimmunol.1201531. Epub 2013 Jul 12.
7
Early signaling events that underlie fate decisions of naive CD4(+) T cells toward distinct T-helper cell subsets.幼稚 CD4(+) T 细胞向不同 T 辅助细胞亚群分化的命运决定所依赖的早期信号事件。
Immunol Rev. 2013 Mar;252(1):12-23. doi: 10.1111/imr.12032.
8
Production and characterization of human soluble CD83 fused with the fragment crystallizable region of human IgG1 in Pichia pastoris.在巴斯德毕赤酵母中表达和鉴定与人 IgG1 的 Fc 段融合的人可溶性 CD83。
Appl Microbiol Biotechnol. 2013 Nov;97(21):9409-17. doi: 10.1007/s00253-013-4732-1. Epub 2013 Feb 8.
9
Multiple interferon regulatory factor and NF-κB sites cooperate in mediating cell-type- and maturation-specific activation of the human CD83 promoter in dendritic cells.多个干扰素调节因子和 NF-κB 结合位点协同作用,介导树突状细胞中人类 CD83 启动子的细胞类型和成熟特异性激活。
Mol Cell Biol. 2013 Apr;33(7):1331-44. doi: 10.1128/MCB.01051-12. Epub 2013 Jan 22.
10
CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2.CD83 刺激的单核细胞通过产生前列腺素 E2 来抑制 T 细胞免疫应答。
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18778-83. doi: 10.1073/pnas.1018994108. Epub 2011 Nov 7.